Islatravir Anhydrous: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Islatravir Anhydrous. Educational only — not medical advice.
Labeled uses
IDVYNSO™ is indicated as a complete two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine [see Microbiology (12.4) and Clinical Studies (14) ].
Source: FDA labeling via NIH DailyMed (set 11aaeb53…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.